Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer

0
125

TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Company's Chief Scientific Officer (CSO).

“Kevin is an ideal addition to our management team given his extensive experience leading drug discovery and development efforts in areas such as oncology and immunology,” said Fahar Merchant, PhD, President and CEO of Medicenna. “We are thrilled to welcome Kevin to Medicenna as his scientific and technical expertise will be instrumental in the development of our novel Superkine and BiSKITs™ platforms and while helping to expand our clinical-stage pipeline.”

Dr. Moulder brings over 30 years of experience in drug discovery and development in the fields of protein design, antibody technology, immuno-oncology, inflammation and autoimmune disease. Following his post-doctoral studies at the NIH, he joined GSK to lead their CD23 program. Thereafter, he served in research and development leadership positions in 9 international biotechnology companies including Biogen where he ran a predictive medicine department. As VP of Research at Domantis, Kevin led the creation of a pipeline of novel single domain antibodies resulting in Domantis' acquisition by GSK. Subsequently, Dr. Moulder served as the CSO of F-Star Therapeutics, where he established the company's bispecific antibody technology and led the translational efforts to identify its first clinical lead. Most recently Kevin held C-level positions at PolyProx Therapeutics Ltd. and Tusk Therapeutics. At Tusk, Kevin directed the development of their anti-CD25 antibody which showed anticancer activity …

Full story available on Benzinga.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here